By proceeding, you agree to our Terms of Use and Privacy Policy.
Pelago Bioscience was founded in 2013 with the aim to develop the patented Cellular Thermal Shift Assay (CETSA®) for maximum utility and customer value in drug discovery and diagnostics.
25-28 October 2022
The 5th Annual Targeted Protein Degradation Summit is the world leading industry-dedicated conference that spans the full drug development pipeline from discovery through to the clinic addressing key challenges to make this exciting new modality a th
Event Ended
USA
Paid
Boston
17-18 November 2022
The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling.
10-13 April 2023
Drug Discovery Chemistry is a dynamic conference for medicinal and biophysical chemists working in pharma, biotech, and academia. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting op
Hybrid
San Diego
25-25 September 2023
The coronavirus pandemic ignited interest in learning more about immune responses to infections, their downstream effects, and how they can be modulated. It also gave rise to increased awareness of the role of immunity in diseases like cancer, neurod
Washington, DC
There has been growing interest in targeting kinases such as JAK, TYK, IRAK, SIK, CDK, MEK, ERK, RTK, PLK, PI3K, ALK, MAPK, GSK, LRRK, and more for their role in neurodegeneration, inflammation, cancer, autoimmune, and other disorders. However, targe
25-28 September 2023
Discovery on Target (DOT) highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.
26-27 September 2023
Cambridge Healthtech Institute’s two-part conference on Artificial Intelligence (AI)/Machine Learning (ML)-Enabled Drug Discovery will highlight the increasing use of computational tools, AI modeling, algorithms, and data science for identifying nove
While finding novel druggable targets and drug modalities for therapeutic intervention remains a top priority for the pharma/biotech industry, identifying and validating "good" targets and leads remains challenging. Cambridge Healthtech Institute’s c
Cambridge Healthtech Institute's GPCR-Based Drug Discovery conference is now in its 18th year. G protein-coupled receptors (GPCRs), because of their central role in so many cellular processes, are still among the largest class of molecules modulated
Small molecule-based therapeutic options against traditionally hard-to-drug intracellular oncology targets (like KRAS) are being discovered at a more rapid pace and a few have even reached the market in the past few years. Not only do small molecules
As the industry increasingly shifts its attention to biologics, more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For these large target classes, biologics offer improved selectivity, an altern
A new generation of molecules are being developed to disrupt protein-protein interactions and to hijack the cell’s natural machinery for targeted protein degradation. Proteolysis-targeting chimeras (PROTACs), molecular glues, and other modalities are
Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets conference focuses on therapeutic candidates in clinical or earlier stage development that modulate molecules or cellular processes involved in neurodegenerative diseases, especial
27-28 September 2023
Cambridge Healthtech Institute’s annual Lead Generation Strategies conference illuminates the latest approaches used by medicinal, biophysical and computational chemists to discover and develop small molecules (and now slightly larger molecules that
Fibrosis can be viewed as the end-stage of chronic inflammation. Fibrosis and inflammation are related to the immune system gone awry and both underlie many conditions related to aging and therefore are increasing in prevalence in the US. Cambridge H
Transcription factors are proteins with DNA-binding domains that are involved in gene transcription. They are key cell regulators and alterations in their structure, binding, or activity are often found associated with many abnormalities in cellular
30-02 November 2023
The 6th Targeted Protein Degradation Summit is the premier event for professionals in the field of protein degradation drug development. Returning to Boston in 2023, this summit has established itself as the longest-standing and most comprehensive ga